The EPS miss and continued cash burn are negative, but the Mayo collaboration and pipeline catalysts (SC451 IND, SG293 data) could drive near-term volatility. Watch for IND filing updates and ASGCT presentation on May 12 for SG293 surrogate data, positive results could reverse sentiment. Cash runway into 2027 reduces near-term dilution risk.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $3.26entry
- T+1 · 6mo ago 0.00%α −0.54% · $3.26
- T+5 · 6mo ago −6.75%α −6.83% · $3.04
- T+20 · 5mo ago −13.50%α −11.77% · $2.82
- T+60 · 3mo ago +4.60%α +0.22% · $3.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but worse than the $0.15 consensus estimate. The company highlighted progress toward clinical trials for SC451 (type 1 diabetes) and SG293 (non-Hodgkin lymphoma), a strategic collaboration with Mayo Clinic including a $25M equity investment, and a cash runway into 2027. The EPS miss and lack of revenue are bearish, but the pipeline progress and collaboration provide some offset.
Key Financial Metrics
Key Facts
- GAAP net loss per share of $0.17 vs consensus estimate of $0.15 (miss of 13.3%)
- Net loss of $47.2M in Q1 2026 vs $49.4M in Q1 2025
- Cash, cash equivalents, and marketable securities of $101.1M as of March 31, 2026, down from $138.4M at year-end 2025
- Non-GAAP operating cash burn of $37.0M in Q1 2026 vs $46.6M in Q1 2025
- Entered strategic collaboration with Mayo Clinic for SC451, including $25M equity investment with option for additional $25M
- Reported positive 14-month clinical data for UP421 (HIP-modified islet cells) showing ongoing survival and function without immunosuppression
- Expects to file IND and begin Phase 1 trial for SC451 later in 2026
- Expects to begin clinical study for SG293 (in vivo CAR T) later in 2026
- Appointed Brian Piper as new CFO
- No revenue reported; pre-revenue biotechnology company
Financial Impact
EPS miss of $0.02 vs consensus; cash burn of $37M in the quarter; cash runway into 2027
Risk Factors
- Clinical trial delays or failures for SC451 or SG293
- Continued cash burn without near-term revenue
- Dilution risk from ATM facility and potential future equity offerings
- Dependence on Mayo Clinic collaboration for SC451 development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292311 |
Track record
12 reports on SANA
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.93% at T+60 after the Apr 13, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Viewing Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers